Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Testing A New Model For Personalized Drug Development

This article was originally published in RPM Report

Executive Summary

Pfizer, Genentech, AstraZeneca and Amgen drugs will be studied in a lung cancer “master protocol” set to launch March 1. The trial could revolutionize the treatment of a rare, serious disease – but advocates have an even bigger goal: “changing the entire paradigm for drug development.”

You may also be interested in...



FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control

FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA commissioner Janet Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

Topics

Related Companies

UsernamePublicRestriction

Register

PS081079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel